The efficacy and safety of ivabradine hydrochloride versus atenolol in Chinese patients with chronic stable angina pectoris

Li, Yan; Jing, Linde; Li, Yishi; Jiang, Jinfa; Wang, Zhirong; Wei, Jin; Li, Xingtao; Wang, Lin; Xia, Hao; Li, Tianfa; Liu, Shaowen; Xing, Bo; Yang, Zhenyu; Lu, Qinghua; Rong-jian, Jiang; Xie, Ping; Shou, Xiling; Wang, Xiaofeng; Jia, Yanbin

doi:10.1002/pds.3628

Cited by 8 publications

(21 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Furthermore, patients treated with the higher dose of metoprolol succinate did not report additional AEs. The incidence of AEs during the study was comparable to that at 12 weeks of treatment with 5-7.5 mg ivabradine b.i.d or 12.5-25 mg atenolol b.i.d in Chinese patients with stable angina, where the reported incidence of all AEs was 27.4% 22, further supporting the proposition that 190 mg metoprolol succinate can be safely prescribed for Chinese patients.…”

Section: Discussionsupporting

confidence: 67%

Effect of Metoprolol Succinate in Patients with Stable Angina and Elevated Heart Rate Receiving Low-Dose β-Blocker Therapy

Jiang¹,

Cong²,

Zhang³

et al. 2017

Int. J. Med. Sci.

View full text Add to dashboard Cite

Aims: β-blockers are underused in Chinese patients with coronary heart disease. The prescribed dose is often low. The aim of this study was to investigate the effect of metoprolol succinate doses of 95 mg and 190 mg on heart rate (HR) control, as well as drug tolerance, in Chinese patients with stable angina, low-dose β-blocker use and unsatisfactory HR control.Methods: This was a multicenter, randomized, open-label, parallel-group trial in 15 clinical sites. Patients with stable angina, taking low-dose β-blockers (equivalent to metoprolol succinate 23.75-47.5 mg/day), and having a resting HR of ≥ 65 bpm were enrolled and randomized to either the metoprolol 95-mg group or the 190-mg group. The change in 24-h average HR from baseline recorded by Holter monitoring and the percentages of patients with resting HR controlled to ≤ 60 bpm were compared between the two groups.Results: Two hundred thirty-one patients entered the intent-to-treat population for the main analysis. The change in 24-h average HR from baseline was -0.62 ± 0.66 bpm in the 95 mg group and -2.99 ± 0.62 bpm in the 190 mg group (p = 0.0077) after 8 weeks of treatment. The percentages of patients with resting HR controlled to ≤ 60 bpm were 24.1% (95% CI: 16.35%, 31.93%) and 40.0% (95% CI: 31.05%, 48.95%), respectively (p = 0.0019). Only 4 and 2 of the patients, respectively, discontinued the study drugs because of hypotension or bradycardia.Conclusions: The metoprolol succinate dose of 190 mg is superior to the 95 mg dose in terms of HR control, in Chinese patients with stable angina, low-dose β-blocker use and unsatisfactory HR control. Both doses were well tolerated.

show abstract

Section: Discussionsupporting

confidence: 67%

Effect of Metoprolol Succinate in Patients with Stable Angina and Elevated Heart Rate Receiving Low-Dose β-Blocker Therapy

Jiang¹,

Cong²,

Zhang³

et al. 2017

Int. J. Med. Sci.

View full text Add to dashboard Cite

show abstract

“…To make full use of the data, we treated 12 weeks as 3 months. 6 To assess the effectiveness of ivabradine in stable angina pectoris, the patients were grouped according to whether they were followed up for less than or at least 3 months. In a separate analysis, the patients were grouped according to whether the control group received a placebo or BB.…”

Section: Methodsmentioning

confidence: 99%

Effectiveness of Ivabradine in Treating Stable Angina Pectoris

Chen

et al. 2016

Medicine

View full text Add to dashboard Cite

Many studies show that ivabradine is effective for stable angina.This meta-analysis was performed to determine the effect of treatment duration and control group type on ivabradine efficacy in stable angina pectoris.Relevant articles in the English language in the PUBMED and EMBASE databases and related websites were identified by using the search terms “ivabradine,” “angina,” “randomized controlled trials,” and “Iva.” The final search date was November 2, 2015.Articles were included if they were published randomized controlled trials that related to ivabradine treatment of stable angina pectoris.Patients with stable angina pectoris were included.The patients were classified according to treatment duration (<3 vs ≥3 months) or type of control group (placebo vs beta-receptor blocker). Angina outcomes were heart rate at rest or peak, exercise duration, and time to angina onset.Seven articles were selected. There were 3747 patients: 2100 and 1647 were in the ivabradine and control groups, respectively. The ivabradine group had significantly longer exercise duration when they had been treated for at least 3 months, but not when treatment time was less than 3 months. Ivabradine significantly improved time to angina onset regardless of treatment duration. Control group type did not influence the effect of exercise duration (significant) or time to angina onset (significant).Compared with beta-blocker and placebo, ivabradine improved exercise duration and time to onset of angina in patients with stable angina. However, its ability to improve exercise duration only became significant after at least 3 months of treatment.

show abstract

“…Было найдено 72 РКИ по сравнительной оценке двух антиангинальных препаратов, которые были опубликованы с 1964г и в целом включали 7034 больных. В целом критериям включения удовлетворяли 13 РКИ [29][30][31][32][33][34][35][36][37][38][39][40][41], в 9 из которых было включено от 100 до 300 больных (>50 больных в каждой группе). В остальные 4 РКИ было включено >300 больных (>150 больных в каждую группу) [33,38,39,41].…”

Section: сравнительная эффективность современных противоишемических сunclassified

“…Однако и при анализе таких РКИ ни в одном случае не были отмечены преимущества приема одного противоишемического препарата по сравнению с другим (в таких исследованиях изучали эффекты приема β-блокаторов, АК и ингибиторов I f каналов). Причем в 3 из этих РКИ были сходные результаты для сравниваемых препаратов и в 1 РКИ почти сходное улучшение в переносимости физической нагрузки [33,38,41]. Причем следует отметить, что большинство РКИ, включенных в метаанализ, были выполнены до 2010г [41].…”

Section: сравнительная эффективность современных противоишемических сunclassified

“…Причем в 3 из этих РКИ были сходные результаты для сравниваемых препаратов и в 1 РКИ почти сходное улучшение в переносимости физической нагрузки [33,38,41]. Причем следует отметить, что большинство РКИ, включенных в метаанализ, были выполнены до 2010г [41].…”

Section: сравнительная эффективность современных противоишемических сunclassified

See 1 more Smart Citation

Modern strategy of treating patients with coronary artery disease: complementarity principle in therapy and new ideas about its role and components

2019

View full text Add to dashboard Cite

В статье рассматриваются современные представления о роли механической реваскуляризации миокарда и лекарственной противоишемической терапии в лечении больных со стабильным течением ишемической болезни сердца (ИБС). Приводятся современные данные о сравнительной эффективности противоишемических препаратов, которые стали основанием для разработки концепции "бриллиантового подхода" к лечению больных со стабильным течением ИБС, которая предлагается вместо стандартной тактики с использованием иерархического подхода к выбору противоишемических средств. Рассматриваются особенности применения противоишемических препаратов в определенных клинических ситуациях, у больных с наиболее распространенными сопутствующими заболеваниями или осложнениями ИБС, а также при вариантах ИБС, в развитии которых играют роль специфические патофизиологические звенья. Ключевые слова: ишемическая болезнь сердца, тактика лечения, механическая реваскуляризация. Конфликт интересов: не заявлен.

show abstract

The efficacy and safety of ivabradine hydrochloride versus atenolol in Chinese patients with chronic stable angina pectoris

Abstract: Iva is effective in reducing heart rates and improving exercise capacity and noninferior to Aten in Chinese patients with chronic stable angina pectoris. Iva is well tolerated and safe.

Cited by 8 publications

References 39 publications

Effect of Metoprolol Succinate in Patients with Stable Angina and Elevated Heart Rate Receiving Low-Dose β-Blocker Therapy

Effect of Metoprolol Succinate in Patients with Stable Angina and Elevated Heart Rate Receiving Low-Dose β-Blocker Therapy

Effectiveness of Ivabradine in Treating Stable Angina Pectoris

Modern strategy of treating patients with coronary artery disease: complementarity principle in therapy and new ideas about its role and components

Contact Info

Product

Resources

About